BetaGlue Therapeutics S.p.A. is a clinical-stage Italian biotech company headquartered in Milan, dedicated to developing next-generation targeted radiotherapy platforms and nuclear therapies for solid tumors.
Subscribe to see BetaGlue’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BetaGlue is a medical technology company headquartered in Italy. It has raised at least $15.1M across the 2 funding rounds on record. Its most recent funding round raised $6.5M in December 2024. Xcout tracks 3 named people at BetaGlue, including Dr. Colin Story (CEO).
As of 16 November 2026. Source: Xcout Intel.
At least $15.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $6.5M | 6 named | |
| — | $8.6M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 14 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of BetaGlue's closest competitors — see the full list of competitors and alternatives →
Newrite Medical is a developer of targeted therapeutic and diagnostic agents for nuclear medicine applications. The company provides radiopharmaceutical development, isotope production, and radioligand therapy technologies.
BeBetter Med Inc. is a biotechnology company focused on developing next-generation targeted therapeutics. The company provides advanced medical treatments and pharmaceutical research solutions for patients and healthcare sectors.
January Therapeutics, Inc. is a privately held biotechnology company founded in 2017 and based in California, focused on developing next-generation targeted anti-cancer therapies.
Golgenia is a research and development company operating in the drug discovery industry and advancing its GSL oncology platform. Headquartered in Milan, Italy, the company closed a 1.5 million euro Series A financing to support its pipeline toward first-in-human trials.
Nuclidium is a precision oncology company headquartered in Basel, Switzerland. It specializes in developing next-generation copper radiotheranostics to provide personalized treatment options for cancer patients at various stages.
Pentixapharm Holding AG is a clinical-stage radiopharmaceutical company that develops first-in-class radiopharmaceutical diagnostics and therapeutics, focusing on CXCR4-targeted compounds. The company serves patients and healthcare providers by advancing drug candidates through clinical trials, including Phase III-ready programs.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about BetaGlue? Suggest a correction · Work at BetaGlue? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.